Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

101. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Full Text available with Trip Pro

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared (...) status of 0 or 1. Patients were randomly assigned 2:1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg or ipilimumab 3 mg/kg plus placebo, every 3 weeks for four doses. Subsequently, patients assigned to nivolumab plus ipilimumab received nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity, whereas patients allocated to ipilimumab alone received placebo every 2 weeks during this phase. Randomisation was done via an interactive voice

2016 EvidenceUpdates

102. Nivolumab in combination with ipilimumab for treating advanced melanoma

Nivolumab in combination with ipilimumab for treating advanced melanoma Niv Nivolumab in combination with olumab in combination with ipilimumab for treating advanced ipilimumab for treating advanced melanoma melanoma T echnology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta400 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

103. Nivolumab - Addendum to Commission A15-27

Nivolumab - Addendum to Commission A15-27 1 Translation of addendum A15-50 Nivolumab (Addendum zum Auftrag A15-27) (Version 1.0; Status: 11 December 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 December 2015 1.0 Commission: A15-50 Version: Status: IQWiG Reports – Commission No. A15-50 Nivolumab (Addendum to Commission A15-27) 1 Addendum A15 (...) -50 Version 1.0 Nivolumab (Addendum to Commission A15-27) 11 December 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (Addendum to Commission A15-27) Commissioning agency: Federal Joint Committee Commission awarded on: 24 November 2015 and 1 December 2015 Internal Commission No.: A15-50 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

104. Nivolumab - Addendum to Commission A15-32

Nivolumab - Addendum to Commission A15-32 1 Translation of addendum A15-58 Nivolumab – Addendum zum Auftrag A15-32 (Version 1.0; Status: 13 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 January 2016 1.0 Commission: A15-58 Version: Status: IQWiG Reports – Commission No. A15-58 Nivolumab – Addendum to Commission A15-32 1 Addendum A15 (...) -58 Version 1.0 Nivolumab – Addendum to Commission A15-32 13 January 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab – Addendum to Commission A15-32 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2015 Internal Commission No.: A15-58 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

105. Nivolumab (Opdivo) for treatment of non-small cell lung cancer

Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for treatment of non-small cell lung cancer. Lansdale: HAYES, Inc.. Healthcare (...) Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based

2016 Health Technology Assessment (HTA) Database.

106. [Nivolumab - addendum to commission A15-32]

[Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab: addendum zum auftrag A15-32; auftrag A15-58. [Nivolumab - addendum to commission A15-32] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 356. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Programmed Cell Death 1 Receptor Language Published German Country of organisation Germany English

2016 Health Technology Assessment (HTA) Database.

107. Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer - first line

Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer - first line Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR (...) HSRIC. Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Nivolumab is a new drug for the treatment of a specific type of non-small cell lung cancer. It is given as a drip

2016 Health Technology Assessment (HTA) Database.

108. Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer - first line

Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer - first line Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for stage IV (...) or recurrent non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Nivolumab is a new drug for the treatment of non-small cell lung cancer. It is given as a drip into a vein once every two weeks. Some studies have suggested nivolumab may

2016 Health Technology Assessment (HTA) Database.

109. Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer - second line

Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer - second line Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer – second line Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo (...) will be diagnosed with disease that has spread outside of the bladder. Nivolumab is a new antibody drug for the treatment of bladder cancer and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. A study underway at the moment is aiming to find out how well nivolumab works in people whose first treatment has failed and whose disease has spread. If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with bladder

2016 Health Technology Assessment (HTA) Database.

110. Nivolumab for follicular non-Hodgkin lymphoma Ä third line

Nivolumab for follicular non-Hodgkin lymphoma Ä third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab for follicular non-Hodgkin lymphoma ─ third line. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2016 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. It often progresses slowly, with patients showing no symptoms for many years. Nivolumab is a new antibody drug for the treatment of follicular lymphoma that is delivered straight into the bloodstream via a drip. Some studies have

2016 Health Technology Assessment (HTA) Database.

111. Nivolumab for treating advanced (unresectable or metastatic) melanoma

Nivolumab for treating advanced (unresectable or metastatic) melanoma Niv Nivolumab for treating advanced olumab for treating advanced (unresectable or metastatic) melanoma (unresectable or metastatic) melanoma T echnology appraisal guidance Published: 18 February 2016 nice.org.uk/guidance/ta384 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 36Contents Contents 1

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

112. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. Full Text available with Trip Pro

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 26840145 2016 02 05 2018 12 02 1533-4406 374 5 2016 02 04 The New England journal of medicine N. Engl. J. Med. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 492-3 10.1056/NEJMc1514790 Hasegawa Takahiro T Uno Hajime H Wei Lee-Jen LJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Antineoplastic Agents 0 Taxoids AIM IM N Engl J Med. 2016 Feb 4;374(5):493-4 26840144 N Engl J Med. 2015 Oct 22;373

2016 NEJM

113. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. (Abstract)

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 26840144 2016 02 05 2018 12 02 1533-4406 374 5 2016 02 04 The New England journal of medicine N. Engl. J. Med. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 493-4 10.1056/NEJMc1514790 Borghaei Hossein H Brahmer Julie J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Antineoplastic Agents 0 Taxoids AIM IM N Engl J Med. 2016 Feb 4;374(5):493 26840146 N Engl J Med. 2015 Oct 22;373(17):1627-39

2016 NEJM

114. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. Full Text available with Trip Pro

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 26840146 2016 02 05 2018 12 02 1533-4406 374 5 2016 02 04 The New England journal of medicine N. Engl. J. Med. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. 493 10.1056/NEJMc1514790 Gyawali Bishal B Ota Akiko A Ando Yuichi Y eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Antineoplastic Agents 0 Taxoids AIM IM N Engl J Med. 2016 Feb 4;374(5):493-4 26840144 N Engl J Med. 2015 Oct 22;373(17

2016 NEJM

115. [Nivolumab: addendum to Commission A15-27]

[Nivolumab: addendum to Commission A15-27] Nivolumab (addendum zum Auftrag A15-27) [Nivolumab: addendum to Commission A15-27] Nivolumab (addendum zum Auftrag A15-27) [Nivolumab: addendum to Commission A15-27] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut (...) für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (addendum zum Auftrag A15-27). [Nivolumab: addendum to Commission A15-27] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 346. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Agents; Humans Language Published German Country of organisation Germany English summary There is no English language summary

2016 Health Technology Assessment (HTA) Database.

116. Nivolumab (melanoma): Addendum to Commission A16-35

Nivolumab (melanoma): Addendum to Commission A16-35 Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68. [Nivolumab (melanoma): Addendum to Commission A16-35] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 465. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published German Country

2016 Health Technology Assessment (HTA) Database.

117. [Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)] Nivolumab – nutzenbewertung gemäß § 35a SGB V [Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)] Nivolumab – nutzenbewertung gemäß § 35a SGB V [Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation IQWiG. Nivolumab – nutzenbewertung gemäß § 35a SGB V. [Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 331. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans Language Published German Country of organisation Germany English summary

2016 Health Technology Assessment (HTA) Database.

118. [Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)] Nivolumab (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)] Nivolumab (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment (...) )] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Nivolumab (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

2016 Health Technology Assessment (HTA) Database.

119. Combined Nivolumab and Ipilimumab or monotherapy in hepatocellular carcinoma: a systematic review

Combined Nivolumab and Ipilimumab or monotherapy in hepatocellular carcinoma: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

120. Evaluation of the clinical and cost-effectiveness of everolimus, nivolumab, axitinib, sorafenib and sunitinib in previously treated renal cell carcinoma

Evaluation of the clinical and cost-effectiveness of everolimus, nivolumab, axitinib, sorafenib and sunitinib in previously treated renal cell carcinoma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO